Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures

Brain Research

Volumn 1203, Issue , 2008, Pages 149-159

  Kääriäinen, Tiina M ^a   Piltonen, Marjo ^b   Ossola, Bernardino ^b   Kekki, Heli ^a   Lehtonen, Šárka ^a   Nenonen, Terhi ^b   Lecklin, Anne ^a   Raasmaja, Atso ^b   Männistö, Pekka T ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

6 Hydroxydopamine; Neuroprotection; Parkinson's disease; Quercetin; Rotational behavior; SH SY5Y cells

Indexed keywords

APOMORPHINE; DEXAMPHETAMINE; DOPAMINE; OXIDOPAMINE; QUERCETIN; REACTIVE OXYGEN METABOLITE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; MALE; MEDIAL FOREBRAIN BUNDLE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANIMALS; ANTIOXIDANTS; APOMORPHINE; BEHAVIOR, ANIMAL; CELL LINE, TUMOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MOTOR ACTIVITY; NEUROBLASTOMA; OXIDOPAMINE; PARKINSON DISEASE; QUERCETIN; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TETRAZOLIUM SALTS; THIAZOLES; TYROSINE 3-MONOOXYGENASE;

PARKINSONIA; RATTUS;

EID: 40949085989     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.01.089     Document Type: Article

References (48)

1. Abrous D.N., Rivet J.M., Le Moal M., and Herman J.P. Similar post-lesion receptor readjustments following the unilateral 6-hydroxydopamine lesion of the dopaminergic mesotelencephalic system in neonatal and adult rats. Brain Res. 526 2 (1990) 195-202
2. Aguiar L.M., Vasconcelos S.M., Sousa F.C., and Viana G.S. Melatonin reverses neurochemical alterations induced by 6-OHDA in rat striatum. Life Sci. 70 9 (2002) 1041-1051
3. Airavaara M., Mijatovic J., Vihavainen T., Piepponen T.P., Saarma M., and Ahtee L. In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 59 6 (2006) 321-329
4. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 2 (2001) 135-172
5. Boots A.W., Li H., Schins R.P., Duffin R., Heemskerk J.W., Bast A., and Haenen G.R. The quercetin paradox. Toxicol. Appl. Pharmacol. 222 1 (2007) 89-96
6. Cadet J.L. Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice. Parkinsonism Relat. Disord. 8 2 (2001) 85-90
7. Choi W.S., Yoon S.Y., Oh T.H., Choi E.J., O'Malley K.L., and Oh Y.J. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 57 1 (1999) 86-94
8. Dajas F., Rivera F., Blasina F., Arredondo F., Echeverry C., Lafon L., Morquio A., and Heizen H. Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox. Res. 5 6 (2003) 425-432
9. de Boer V.C., Dihal A.A., van der Woude H., Arts I.C., Wolffram S., Alink G.M., Rietjens I.M., Keijer J., and Hollman P.C. Tissue distribution of quercetin in rats and pigs. J. Nutr. 135 7 (2005) 1718-1725
10. Fahn S., and Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32 6 (1992) 804-812
11. Fiorani M., De Sanctis R., Menghinello P., Cucchiarini L., Cellini B., and Dacha M. Quercetin prevents glutathione depletion induced by dehydroascorbic acid in rabbit red blood cells. Free Radic. Res. 34 6 (2001) 639-648
12. Heim C., Kolasiewicz W., Kurz T., and Sontag K.H. Behavioral alterations after unilateral 6-hydroxydopamine lesions of the striatum. Effect of alpha-tocopherol. Pol. J. Pharmacol. 53 5 (2001) 435-448
13. Hollman P.C., vd Gaag M., Mengelers M.J., van Trijp J.M., de Vries J.H., and Katan M.B. Absorption and disposition kinetics of the dietary antioxidant quercetin in man. Free Radic. Biol. Med. 21 5 (1996) 703-707
14. Hosokawa N., Hirayoshi K., Nakai A., Hosokawa Y., Marui N., Yoshida M., Sakai T., Nishino H., Aoike A., Kawai K., and Nagata K. Flavonoids inhibit the expression of heat shock proteins. Cell Struct. Funct. 15 6 (1990) 393-401
15. Huotari M., Kukkonen K., Liikka N., Potasev T., Raasmaja A., and Männistö P.T. Effects of histamine H(3)-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat. Disord. 6 3 (2000) 159-164
16. Huotari M., García-Horsman J.A., Karayiorgou M., Gogos J.A., and Männistö P.T. D-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berl). 172 1 (2004) 1-10
17. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 (discussion S36-28)
18. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 6 Suppl. 3 (1996) S161-S170
19. Jenner P., and Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44 3 Suppl. 1 (1998) S72-S84
20. Karstaedt P.J., Kerasidis H., Pincus J.H., Meloni R., Graham J., and Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp. Neurol. 126 1 (1994) 25-30
21. Kirik D., Rosenblad C., and Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 2 (1998) 259-277
22. Kumar R., Agarwal A.K., and Seth P.K. Free radical-generated neurotoxicity of 6-hydroxydopamine. J. Neurochem. 64 4 (1995) 1703-1707
23. Lee E.J., Chen H.Y., Wu T.S., Chen T.Y., Ayoub I.A., and Maynard K.I. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats. J. Neurosci. Res. 68 5 (2002) 636-645
24. Levy J., Teuerstein I., Marbach M., Radian S., and Sharoni Y. Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin. Biochem. Biophys. Res. Commun. 123 3 (1984) 1227-1233
25. Lindholm P., Voutilainen M.H., Laurén J., Peränen J., Leppänen V.M., Andressoo J.O., Lindahl M., Janhunen S., Kalkkinen N., Timmusk T., Tuominen R.K., and Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448 7149 (2007) 73-77
26. Liu Y., Peterson D.A., Kimura H., and Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 69 2 (1997) 581-593
27. Maňáková Š., Singh A., Kääriäinen T., Taari H., Kulkarni S.K., and Männistö P.T. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells. Brain Res. 1038 1 (2005) 83-91
28. Mijatovic J., Airavaara M., Planken A., Auvinen P., Raasmaja A., Piepponen T.P., Costantini F., Ahtee L., and Saarma M. Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. J. Neurosci. 27 18 (2007) 4799-4809
29. Mira L., Fernandez M.T., Santos M., Rocha R., Florêncio M.H., and Jennings K.R. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Radic. Res. 36 11 (2002) 1199-1208
30. Murota K., and Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch. Biochem. Biophys. 417 1 (2003) 12-17
31. Naidu P.S., Singh A., and Kulkarni S.K. Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology 44 8 (2003) 1100-1106
32. Nakamura Y., Ishimitsu S., and Tonogai Y. Effects of quercetin and rutin on serum and hepatic lipid concentrations, fecal steroid excretion and serum antioxidant properties. J. Health Sci. 46 4 (2000) 229-240
33. Nobre Junior H.V., Cunha G.M., Maia F.D., Oliveira R.A., Moraes M.O., and Rao V.S. Catechin attenuates 6-hydroxydopamine (6-OHDA)-induced cell death in primary cultures of mesencephalic cells. Comp. Biochem. Physiol., Toxicol. Pharmacol. 136 2 (2003) 175-180
34. Olanow C.W. Oxidation reactions in Parkinson's disease. Neurology 40 10 Suppl. 3 (1990) (suppl 32-37)
35. Patil C.S., Singh V.P., Satyanarayan P.S., Jain N.K., Singh A., and Kulkarni S.K. Protective effect of flavonoids against aging-and lipopolysaccharide-induced cognitive impairment in mice. Pharmacology 69 2 (2003) 59-67
36. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
37. Puttonen K.A., Maňáková Š., Raasmaja A., and Männistö P.T. Increased p53 levels without caspase-3 activity and change of cell viability in 6-hydroxydopamine-treated CV1-P cells. Cell Biol. Toxicol. 19 3 (2003) 177-187
38. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J. Nutr. Biochem. 18 7 (2007) 427-442
39. Sauer H., Rosenblad C., and Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U. S. A. 92 19 (1995) 8935-8939
40. Sharma R., McMillan C.R., Tenn C.C., and Niles L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068 1 (2006) 230-236
41. Singh A., Naidu P.S., and Kulkarni S.K. Quercetin potentiates l-dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology 68 2 (2003) 81-88
42. Supino R. MTT assays. Methods Mol. Biol. 43 (1995) 137-149
43. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell. 6 4 (2000) 909-919
44. Wei Y.Q., Zhao X., Kariya Y., Fukata H., Teshigawara K., and Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res. 54 18 (1994) 4952-4957
45. Wätjen W., Michels G., Steffan B., Niering P., Chovolou Y., Kampkötter A., Tran-Thi Q.H., Proksch P., and Kahl R. Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis. J. Nutr. 135 3 (2005) 525-531
46. Youdim K.A., Qaiser M.Z., Begley D.J., Rice-Evans C.A., and Abbott N.J. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic. Biol. Med. 36 5 (2004) 592-604
47. Yuan H., Sarre S., Ebinger G., and Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J. Neurosci. Methods 144 1 (2005) 35-45
48. Zbarsky V., Datla K.P., Parkar S., Rai D.K., Aruoma O.I., and Dexter D.T. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic. Res. 39 10 (2005) 1119-1125